CWA
LOGC

Capital Wealth Alliance’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Capital Wealth Alliance’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-500
Closed -$5K – 384
2019
Q4 		$5K Buy
+500
New +$4.52K ﹤0.01% 253

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Wealth Alliance's LOGC Position: Q1 2020 in Review

Capital Wealth Alliance sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2020, closing a stake of 500 shares — an estimated $5K sold.

Capital Wealth Alliance first reported a position in LOGC in Q4 2019 and held it in 1 quarter. The position peaked at $5K in Q4 2019. 43 funds tracked by Wall St. Rank hold LOGC as of Q1 2020.

  • Capital Wealth Alliance reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Capital Wealth Alliance sold 500 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $5K.
  • Capital Wealth Alliance first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Capital Wealth Alliance's LogicBio Therapeutics, Inc. Common Stock position peaked at $5K in Q4 2019.
  • 43 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Capital Wealth Alliance's 13F filing for Q1 2020, filed 28 Apr 2020.